Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
715.66
+12.36 (+1.76%)
Streaming Delayed Price
Updated: 10:45 AM EDT, Mar 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about argenx SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
↗
April 08, 2025
Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.
Via
Benzinga
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
April 08, 2025
From
argenx SE
Via
GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
↗
March 31, 2025
Via
Benzinga
Looking Into argenx's Recent Short Interest
↗
March 26, 2025
Via
Benzinga
P/E Ratio Insights for argenx
↗
March 20, 2025
Via
Benzinga
What Analysts Are Saying About argenx Stock
↗
March 04, 2025
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
↗
March 04, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
↗
February 19, 2025
Via
Benzinga
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
March 07, 2025
From
argenx SE
Via
GlobeNewswire
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
↗
March 04, 2025
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
Via
Investor's Business Daily
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
February 27, 2025
From
argenx SE
Via
GlobeNewswire
argenx to Present at TD Cowen 45th Annual Healthcare Conference
February 25, 2025
From
argenx SE
Via
GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
↗
January 30, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
↗
January 16, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
↗
January 03, 2025
Via
Benzinga
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
February 20, 2025
From
argenx SE
Via
GlobeNewswire
argenx Highlights 2025 Strategic Priorities
January 13, 2025
From
argenx SE
Via
GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
↗
December 18, 2024
Via
Benzinga
Looking Into argenx's Recent Short Interest
↗
December 09, 2024
Via
Benzinga
(ARGX) - Analyzing argenx's Short Interest
↗
November 14, 2024
Via
Benzinga
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
argenx SE
Via
GlobeNewswire
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
December 27, 2024
From
argenx SE
Via
GlobeNewswire
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
↗
December 17, 2024
Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.
Via
Benzinga
argenx to Present at Upcoming Investor Conferences
November 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
November 20, 2024
From
argenx SE
Via
GlobeNewswire
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
↗
November 12, 2024
Via
Benzinga
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
November 11, 2024
From
Zai Lab Limited
Via
Business Wire
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
November 11, 2024
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
